NewsRoom Articles - Page 49 of 236

FridayNov 01, 2024 10:00 am

Study Explores How Antimicrobials Impact the Risk of Developing Parkinson’s Disease

A new study has investigated how exposure to antimicrobials influences the risk of Parkinson's disease development. Parkinson’s disease is a brain disorder that affects an individual’s movement, causing stiffness, tremors as well as issues with coordination and balance. The condition’s symptoms worsen as it progresses. In advanced stages, patients may find it hard to talk and walk. Parkinson’s has no cure and affects more than 8.5 million individuals globally. Projections expect that by 2040, more than 12 million individuals will be living with the disorder. Genetic and environmental factors are said to contribute to the condition’s etiology, with researchers theorizing…

ThursdayOct 31, 2024 10:00 am

New Toolkit Launched to Boost Marburg Screening Readiness in the US

Thus far, Rwanda has confirmed the presence of 64 cases of Marburg virus disease, a type of viral hemorrhagic fever. This virus is transmitted to humans from fruit bats and spreads from one individual to another through human-to-human transmission. According to the WHO, common symptoms of the virus include muscle aches and pains, abdominal pain and cramping, severe watery diarrhea, nausea and vomiting, and a non-itchy rash. The disease has a case fatality ratio of up to 88%, with an average fatality rate of about 50%. Experts note that early symptomatic treatment and supportive care with rehydration improves survival. While…

ThursdayOct 31, 2024 9:45 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Is ‘One to Watch’

Calidi’s unique OV platforms are engineered to protect and amplify virus efficacy, enhancing tumor targeting and patient safety. Calidi’s lead programs, CLD-101, CLD-201, and CLD-400, are advancing through key development stages, with major milestones anticipated, including Phase 1b/2 enrollment for CLD-101 in Q1 2025 and Phase 1 trials for CLD-201 expected in 2H 2024. The company targets a $13-15 billion U.S. market across multiple high-need cancer types, including GBM, TNBC and lung cancer. Calidi’s leadership team combines business, scientific and operational expertise, with a track record of successful exits and growth. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology…

MondayOct 28, 2024 10:30 pm

Brain Organoids Uncover Autism Biology, Possible Treatments

Researchers at the Scripps Research Institute have uncovered new information about autism spectrum disorder (ASD). ASD is a developmental and neurological disorder that affects how an individual interacts with others, behaves, learns and communicates. The disorder’s causes are only partly known, with scientists linking a number of genetic variants to it. For their study, the researchers used stem cells generated from patients with a severe and rare form of the developmental disorder. They focused on MEF2C haploinsufficiency syndrome (MHS), which develops following a genetic variation in the MEF2 gene. They grew the stem cells into mini-brain organoids, which allowed the…

FridayOct 25, 2024 10:00 am

Tech Giants Unveil AI Tools to Support e-Commerce, Healthcare and Video Production

In the last fortnight, leading technology companies have unveiled a number of artificial intelligence tools which could have a huge impact on the e-commerce, healthcare and video production fields. Adobe released its Firefly Video production tool. The model allows corporate users to reduce the costs associated with video production and also streamline the entire process. With the AI tools from Adobe, users can provide text prompts in any of at least 100 supported languages and have custom videos generated. Experts clarify that the efficiency-boosting attributes of these video creation tools shouldn’t be seen as a replacement for humans. Instead, the…

ThursdayOct 24, 2024 10:00 am

Change Healthcare Cyberattack Toll Could Reach Almost $3 Billion This Year

Andrew Witty, the CEO of UnitedHealth Group, gave his testimony on the ransomware attack on Change Healthcare to the Senate Finance Committee in June. The attack occurred in February of this year, with the initial point of entry for the ransomware being a server whose multifactor authentication hadn’t been enabled. This is despite the fact that multifactor authentication is a standard practice for servers exposed to the public internet. After gaining access to the server, the ransomware then acquired access to the Microsoft Active Directory Server. This ransomware attack was a wake-up call to others in the healthcare industry, prompting…

WednesdayOct 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings

Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024. The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients. Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial. The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on…

MondayOct 21, 2024 10:00 am

Study Explores Repurposing Drugs as a Way to Fight Brain Tumor Origins

Glioblastoma multiforme is a common and very aggressive type of cancer that primarily affects an individual’s brain and/or spinal cord. This cancer has an average survival rate of less than 22 months following diagnosis despite standard treatment including chemotherapy, irradiation and surgery. Various factors contribute to this poor outcome, including high tumor recurrence rates, tumor resistance to treatment, and intra-tumoral heterogeneity. In recent years, it has become clear to scientists that not all cells in brain tumors help drive tumor growth. This has led scientists to pay more attention to brain tumor stem cells, which they theorize are the main…

FridayOct 18, 2024 12:00 pm

Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences

Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15. On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York. Clene’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to have a meeting with the FDA leadership in November. Clene (NASDAQ: CLNN) and its…

FridayOct 18, 2024 10:00 am

Toxic Protein Could Be Behind the Development of Amyotrophic Lateral Sclerosis

New research has found that a toxic protein may affect the skeletal muscle tissues, spinal cord, and brain, aiding the development and progression of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis or ALS in short, is an illness that affects an individual’s nervous system, causing nerve cells in the spinal cord and brain to degenerate. As it progresses, this motor neuron illness leads to muscle weakness and atrophy. The research was carried out by a team of scientists from Penn State College of Medicine. It was based on prior studies which implicated mutations of the superoxide dismutase 1 (SOD1) protein in…